Peter J. Rosen - Concepedia

Author

Peter J. Rosen

Also Known As

P J Rosen, P ROSEN, P Rosen, P. J. Rosen, P. Rosen, P.J. Rosen, PETER J. ROSEN, Penni Rosen, Peter J Rosen, Peter J. Rosen

127

Publications

4.2K

Citations

H-Index

104

Concepts

All Affiliations

Tower Cancer Research Foundation The University of Texas MD Anderson Cancer Center University of California, Los Angeles University of Southern California Providence Saint Joseph Medical Center

About

Peter J. Rosen is an author at Tower Cancer Research Foundation specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	30	1.8K
2	Health Sciences	9	9	1.2K
3	Social Sciences	2	2	73
4	Cell Biology	2	2	28
5	Public Health	1	1	24

Peter J. Rosen

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen, Journal of Clinical Oncology Cancer ManagementOligonucleotide MicroarrayPathologyTumor BiologyPfs Ratio	2010	628
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma Ravi Vij, Michael Wang, Jonathan L. Kaufman, Blood	2012	254
Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer Howard I. Scher, Xiaoyu Jia, Kim Chi, Journal of Clinical Oncology	2011	247
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer Mitesh J. Borad, Shantan Reddy, Nathan Bahary, Journal of Clinical Oncology	2014	186
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Cancer	2013	174
Failure of Methylene Blue Treatment in Toxic Methemoglobinemia Peter J. Rosen, Cage S. Johnson, William McGehee, Annals of Internal Medicine Aniline-containing MaterialChemistryMethylene BlueHematologyToxicology	1971	152
A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma Melissa Alsina, Suzanne Trudel, Richard R. Furman, Clinical Cancer Research	2012	143
Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study Nathan Fowler, Brad S. Kahl, Peter P. Lee, Journal of Clinical Oncology	2011	108
Lymphocyte-Depletion Hodgkin's Disease Richard S. Neiman, Peter J. Rosen, Robert J. Lukes New England Journal of Medicine ImmunologyDiagnosisPathologyImmunotherapyCirrhosis	1973	107
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer Walter M. Stadler, David J. Vaughn, Guru Sonpavde, Cancer	2013	106

Page 1